VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced it has received this year’s National Corporate Visionary Award from the Lupus Foundation of America. The award was presented to Dr. Richard and Michelle Glickman and to Aurinia for its long-term commitment to advancing treatments for lupus and lupus nephritis. The award was presented yesterday evening during the Foundation’s Annual Evening of Hope Gala in New York City.
“We are humbled and thrilled to accept this award,” said Dr. Glickman. “The Foundation’s work is crucial to advancing treatments for this disease, and I am proud of the progress Aurinia is making to contribute to the understanding and treatment of the disease. “Our drive to succeed is fueled by patients and their families, who continue to inspire us as we work to make innovative therapies available as quickly and efficiently as possible.”
Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the treatment of LN. The company is headquartered in Victoria, BC and focuses its development efforts globally. www.auriniapharma.com.
About the Lupus Foundation of America
The Lupus Foundation of America is the only national force devoted to solving the mystery of lupus, one of the world’s cruelest, most unpredictable and devastating diseases, while giving caring support to those who suffer from its brutal impact. Through a comprehensive program of research, education, and advocacy, we lead the fight to improve the quality of life for all people affected by lupus. Learn more about the Lupus Foundation of America at lupus.org. For the latest news and updates, follow us on Twitter and Facebook.
We seek safe harbor.
Source: Aurinia Pharmaceuticals Inc.
Released October 12, 2017